Therapeutic Drug Monitoring and Safety of Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease
- PMID: 33248082
- DOI: 10.1016/j.cgh.2020.04.088
Therapeutic Drug Monitoring and Safety of Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease
Comment in
-
Reply.Clin Gastroenterol Hepatol. 2021 Apr;19(4):855-856. doi: 10.1016/j.cgh.2020.06.013. Epub 2020 Nov 26. Clin Gastroenterol Hepatol. 2021. PMID: 33249012 No abstract available.
Comment on
-
Cumulative Exposure to Infliximab, But Not Trough Concentrations, Correlates With Rate of Infection.Clin Gastroenterol Hepatol. 2021 Feb;19(2):288-295.e4. doi: 10.1016/j.cgh.2020.03.018. Epub 2020 Mar 19. Clin Gastroenterol Hepatol. 2021. PMID: 32200087
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
